## Supplementary Table 1: PD-L1 IHC assessment in NSCLC patients with different sites of metastases receiving first-line ICIs monotherapy.

|  |  |
| --- | --- |
| Characteristics | No. of patients (*n*=40) |
| **Tissue origin, *n* (%)** |  |
| Lung | 27 (67.5) |
| Lymph node (thoracic and extra) | 9 (22.5) |
| Pleura tissue | 1 (2.5) |
| Pleura effusion | 1 (2.5) |
| Brain | 1 (2.5) |
| Soft tissue | 1 (2.5) |
| **Sample type, *n* (%)** |  |
| Surgical resection | 7 (17.5) |
| Tissue biopsy | 32 (80.0) |
| Effusion cell block | 1 (2.5) |
| **PD-L1 TPS, *n* (%)** |  |
| 50–59% | 7 (17.5) |
| 60–69% | 7 (17.5) |
| 70–79% | 5 (12.5) |
| 80–89% | 6 (15.0) |
| 90–100% | 15 (37.5) |

ICIs: Immune checkpoint inhibitors; IHC: Immunohistochemistry; NSCLC: Non-small-cell lung cancer; PD-L1: Programmed death-ligand 1; TPS: Tumor proportion score.